{"id":4853,"date":"2026-07-07T22:51:11","date_gmt":"2026-07-07T22:51:11","guid":{"rendered":"https:\/\/fehv.org\/?p=4853"},"modified":"2026-07-07T22:51:14","modified_gmt":"2026-07-07T22:51:14","slug":"resistant-primary-biliary-cholangitis-treatment-with-elafibranor","status":"publish","type":"post","link":"https:\/\/fehv.org\/en\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\/","title":{"rendered":"Resistant primary biliary cholangitis: treatment with Elafibranor"},"content":{"rendered":"\n<p style=\"font-size:18px\">Primary biliary cholangitis (PBC) is a chronic liver disease characterized by inflammation and destruction of the intrahepatic bile ducts, which transport bile from the liver. Its etiology has an autoimmune component, and if left untreated, it can lead to liver cirrhosis.<\/p>\n\n\n\n<p style=\"font-size:18px\"><strong><a href=\"https:\/\/fehv.org\/en\/diseases\/cholangitis\/\" data-type=\"page\" data-id=\"1579\">This disease<\/a><\/strong> has a prevalence of 40 to 50 cases per 100,000 inhabitants. PBC is ten times more common in women than in men and usually manifests between the ages of 35 and 60. This disparity in incidence according to sex is estimated to be due to a greater reactivity of the female immune system, which would lead to a loss of tolerance to biliary autoantigens.<\/p>\n\n\n\n<p style=\"font-size:18px\">Between 60% and 80% of people with PBC are asymptomatic; the remainder may experience fatigue, pruritus, jaundice, and abdominal pain. The usual treatment <strong>consists of administering ursodeoxycholic acid<\/strong> at a dose of about 15 mg per kilogram of body weight. The response rate, defined as the normalization of liver function tests, is approximately 50%. In patients who do not respond to ursodeoxycholic acid, adding bezafibrates to the treatment, achieves a response rate of 30%.<\/p>\n\n\n\n<h2 class=\"wp-block-heading mt-5 mb-4\" id=\"h-clinical-results-of-elafibranor-in-pbc-patients\"><strong>Clinical results of elafibranor in PBC patients<\/strong><\/h2>\n\n\n\n<p style=\"font-size:18px\">Since September 2024, elafibranor has been approved as a new drug for the treatment of primary biliary cholangitis (PBC) resistant to conventional medications. A study presented at the <strong><a href=\"https:\/\/easl.eu\/\" data-type=\"link\" data-id=\"https:\/\/easl.eu\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">European Association for the Study of the Liver<\/a><\/strong> (EASL) Congress evaluated the use of elafibranor in patients who did not respond adequately to ursodeoxycholic acid. The study included 261 patients with PBC, of whom\u00a0 28,5% were receiving a combination of bezafibrates and ursodeoxycholic acid. The results showed that 41% of patients achieved normalization of liver function parameters. Elafibranor was generally well tolerated, although abdominal discomfort, diarrhea, and nausea were observed in some cases, leading to treatment discontinuation in only 5% of participants.<\/p>\n\n\n\n<p style=\"font-size:18px\">In summary, elafibranor is a new drug available for the treatment of PBC that does not respond to standard medications. Both <strong><a href=\"https:\/\/fehv.org\/en\/especialista\/dr-vicente-carreno\/\">Dr. Carre\u00f1o<\/a><\/strong> and the physicians at the foundation take these results into account and will use elafibranor when indicated for PBC.<\/p>\n","protected":false},"excerpt":{"rendered":"Elafibranor is a newly approved treatment for patients with primary biliary cholangitis (PBC) who do not respond adequately to ursodeoxycholic acid. Clinical studies show improved liver function and establish it as a promising therapeutic option.","protected":false},"author":1,"featured_media":4851,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[827,624],"tags":[],"class_list":["post-4853","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-diseases","category-treatments"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.6 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Resistant primary biliary cholangitis: treatment with Elafibranor - Cl\u00ednica FEHV<\/title>\n<meta name=\"description\" content=\"Elafibranor for primary biliary cholangitis improves treatment response in patients with PBC resistant to conventional therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fehv.org\/en\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Resistant primary biliary cholangitis: treatment with Elafibranor\" \/>\n<meta property=\"og:description\" content=\"Elafibranor for primary biliary cholangitis improves treatment response in patients with PBC resistant to conventional therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fehv.org\/en\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\/\" \/>\n<meta property=\"og:site_name\" content=\"Cl\u00ednica FEHV\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/clinicaFEHV\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-07T22:51:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-07T22:51:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fehv.org\/wp-content\/uploads\/2026\/07\/tratamiento-cbp-medicamento.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"ifranco\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ifranco\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\\\/\"},\"author\":{\"name\":\"ifranco\",\"@id\":\"https:\\\/\\\/fehv.org\\\/#\\\/schema\\\/person\\\/5e92ddd4a04516dab21fb5b6fa90b777\"},\"headline\":\"Resistant primary biliary cholangitis: treatment with Elafibranor\",\"datePublished\":\"2026-07-07T22:51:11+00:00\",\"dateModified\":\"2026-07-07T22:51:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\\\/\"},\"wordCount\":333,\"publisher\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fehv.org\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/tratamiento-cbp-medicamento.jpg\",\"articleSection\":[\"Diseases\",\"Treatments\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\\\/\",\"url\":\"https:\\\/\\\/fehv.org\\\/en\\\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\\\/\",\"name\":\"Resistant primary biliary cholangitis: treatment with Elafibranor - Cl\u00ednica FEHV\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fehv.org\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/tratamiento-cbp-medicamento.jpg\",\"datePublished\":\"2026-07-07T22:51:11+00:00\",\"dateModified\":\"2026-07-07T22:51:14+00:00\",\"description\":\"Elafibranor for primary biliary cholangitis improves treatment response in patients with PBC resistant to conventional therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fehv.org\\\/en\\\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fehv.org\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/tratamiento-cbp-medicamento.jpg\",\"contentUrl\":\"https:\\\/\\\/fehv.org\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/tratamiento-cbp-medicamento.jpg\",\"width\":1920,\"height\":1280,\"caption\":\"Foto de Marta Branco: https:\\\/\\\/www.pexels.com\\\/es-es\\\/foto\\\/arreglo-de-herramientas-medicas-y-vacunas-32418225\\\/\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fehv.org\\\/en\\\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/fehv.org\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Resistant primary biliary cholangitis: treatment with Elafibranor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fehv.org\\\/#website\",\"url\":\"https:\\\/\\\/fehv.org\\\/\",\"name\":\"Cl\u00ednica FEHV\",\"description\":\"Web de la Cl\u00ednica de la Fundaci\u00f3n para el Estudio de las Hepatitis Virales\",\"publisher\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fehv.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fehv.org\\\/#organization\",\"name\":\"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV\",\"url\":\"https:\\\/\\\/fehv.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fehv.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fehv.org\\\/wp-content\\\/uploads\\\/2021\\\/03\\\/logo_fib-4.png\",\"contentUrl\":\"https:\\\/\\\/fehv.org\\\/wp-content\\\/uploads\\\/2021\\\/03\\\/logo_fib-4.png\",\"width\":47,\"height\":73,\"caption\":\"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV\"},\"image\":{\"@id\":\"https:\\\/\\\/fehv.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/clinicaFEHV\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fehv.org\\\/#\\\/schema\\\/person\\\/5e92ddd4a04516dab21fb5b6fa90b777\",\"name\":\"ifranco\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a420f8de9a7d1d8c59aac0d97d817361feea70d815889a4d807921618ae04918?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a420f8de9a7d1d8c59aac0d97d817361feea70d815889a4d807921618ae04918?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a420f8de9a7d1d8c59aac0d97d817361feea70d815889a4d807921618ae04918?s=96&d=mm&r=g\",\"caption\":\"ifranco\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Resistant primary biliary cholangitis: treatment with Elafibranor - Cl\u00ednica FEHV","description":"Elafibranor for primary biliary cholangitis improves treatment response in patients with PBC resistant to conventional therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fehv.org\/en\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\/","og_locale":"en_US","og_type":"article","og_title":"Resistant primary biliary cholangitis: treatment with Elafibranor","og_description":"Elafibranor for primary biliary cholangitis improves treatment response in patients with PBC resistant to conventional therapy.","og_url":"https:\/\/fehv.org\/en\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\/","og_site_name":"Cl\u00ednica FEHV","article_publisher":"https:\/\/www.facebook.com\/clinicaFEHV\/","article_published_time":"2026-07-07T22:51:11+00:00","article_modified_time":"2026-07-07T22:51:14+00:00","og_image":[{"width":1920,"height":1280,"url":"https:\/\/fehv.org\/wp-content\/uploads\/2026\/07\/tratamiento-cbp-medicamento.jpg","type":"image\/jpeg"}],"author":"ifranco","twitter_card":"summary_large_image","twitter_misc":{"Written by":"ifranco","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fehv.org\/en\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\/#article","isPartOf":{"@id":"https:\/\/fehv.org\/en\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\/"},"author":{"name":"ifranco","@id":"https:\/\/fehv.org\/#\/schema\/person\/5e92ddd4a04516dab21fb5b6fa90b777"},"headline":"Resistant primary biliary cholangitis: treatment with Elafibranor","datePublished":"2026-07-07T22:51:11+00:00","dateModified":"2026-07-07T22:51:14+00:00","mainEntityOfPage":{"@id":"https:\/\/fehv.org\/en\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\/"},"wordCount":333,"publisher":{"@id":"https:\/\/fehv.org\/#organization"},"image":{"@id":"https:\/\/fehv.org\/en\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\/#primaryimage"},"thumbnailUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2026\/07\/tratamiento-cbp-medicamento.jpg","articleSection":["Diseases","Treatments"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/fehv.org\/en\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\/","url":"https:\/\/fehv.org\/en\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\/","name":"Resistant primary biliary cholangitis: treatment with Elafibranor - Cl\u00ednica FEHV","isPartOf":{"@id":"https:\/\/fehv.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fehv.org\/en\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\/#primaryimage"},"image":{"@id":"https:\/\/fehv.org\/en\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\/#primaryimage"},"thumbnailUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2026\/07\/tratamiento-cbp-medicamento.jpg","datePublished":"2026-07-07T22:51:11+00:00","dateModified":"2026-07-07T22:51:14+00:00","description":"Elafibranor for primary biliary cholangitis improves treatment response in patients with PBC resistant to conventional therapy.","breadcrumb":{"@id":"https:\/\/fehv.org\/en\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fehv.org\/en\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fehv.org\/en\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\/#primaryimage","url":"https:\/\/fehv.org\/wp-content\/uploads\/2026\/07\/tratamiento-cbp-medicamento.jpg","contentUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2026\/07\/tratamiento-cbp-medicamento.jpg","width":1920,"height":1280,"caption":"Foto de Marta Branco: https:\/\/www.pexels.com\/es-es\/foto\/arreglo-de-herramientas-medicas-y-vacunas-32418225\/"},{"@type":"BreadcrumbList","@id":"https:\/\/fehv.org\/en\/resistant-primary-biliary-cholangitis-treatment-with-elafibranor\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fehv.org\/en\/"},{"@type":"ListItem","position":2,"name":"Resistant primary biliary cholangitis: treatment with Elafibranor"}]},{"@type":"WebSite","@id":"https:\/\/fehv.org\/#website","url":"https:\/\/fehv.org\/","name":"Cl\u00ednica FEHV","description":"Web de la Cl\u00ednica de la Fundaci\u00f3n para el Estudio de las Hepatitis Virales","publisher":{"@id":"https:\/\/fehv.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fehv.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fehv.org\/#organization","name":"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV","url":"https:\/\/fehv.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fehv.org\/#\/schema\/logo\/image\/","url":"https:\/\/fehv.org\/wp-content\/uploads\/2021\/03\/logo_fib-4.png","contentUrl":"https:\/\/fehv.org\/wp-content\/uploads\/2021\/03\/logo_fib-4.png","width":47,"height":73,"caption":"Fundaci\u00f3n para el Estudio de las Hepatitis Virales - FEHV"},"image":{"@id":"https:\/\/fehv.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/clinicaFEHV\/"]},{"@type":"Person","@id":"https:\/\/fehv.org\/#\/schema\/person\/5e92ddd4a04516dab21fb5b6fa90b777","name":"ifranco","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a420f8de9a7d1d8c59aac0d97d817361feea70d815889a4d807921618ae04918?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a420f8de9a7d1d8c59aac0d97d817361feea70d815889a4d807921618ae04918?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a420f8de9a7d1d8c59aac0d97d817361feea70d815889a4d807921618ae04918?s=96&d=mm&r=g","caption":"ifranco"}}]}},"_links":{"self":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts\/4853","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/comments?post=4853"}],"version-history":[{"count":3,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts\/4853\/revisions"}],"predecessor-version":[{"id":4856,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/posts\/4853\/revisions\/4856"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/media\/4851"}],"wp:attachment":[{"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/media?parent=4853"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/categories?post=4853"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fehv.org\/en\/wp-json\/wp\/v2\/tags?post=4853"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}